Samsung Bio moves towards evolution as top-tier biotech brand

John Lim, CEO of Samsung BioLogics, held a press conference at Bio USA in Boston, the US on June 5 and revealed the status of the company’s CMO (contract manufacture organization) business and future plans. Samsung BioLogics is moving closer to becoming a top-tier global biotech company.

Samsung moves towards evolution as top-tier biotech brand

According to Boston Consulting Group (via BusinessKorea), the global contract development and manufacturing organization (CDMO) market is expected to grow from $19.1 billion in 2023 to $27 billion in 2026 at an annual growth rate of 12.2 percent over the next three years.

Follow our socials → Google News, Telegram, Twitter, Facebook

Plant 5 is being built with a total investment of $1.52 billion (1.98 trillion won) and will have a 180,000-liter capacity, the same as that of Plant 3. This plant’s completion will raise Samsung BioLogics’ production capacity to an overwhelming 784,000 liters.

“The accelerated completion of Plant 5 will enable Samsung BioLogics to respond to increased orders from customers,” Lim said. “Currently, we have signed production contracts on 12 products with nine clients and are in talks with 29 customers over the production of 44 products.”

In addition, Samsung BioLogics plans to build a second biotech campus with four plants and an open innovation center in addition to the fifth plant. In order to preemptively respond to the ADC market, a production plant exclusively for ADC biopharmaceuticals will be built and the plant will go live in 2024.

| Source |